ESWI Activity Report for 2025
Oral Nirmatrelvir–Ritonavir for Covid-19 in Higher-Risk Outpatients
In two open-label trials, nirmatrelvir–ritonavir did not reduce the incidence of hospitalization or death among vaccinated higher-risk participants with SARS-CoV-2 infection.
Virological characteristics of SARS-CoV-2-related coronaviruses dynamically circulating in Southeast Asia
New insights into the diversity of SC2r-CoVs dynamically co-circulating in Southeast Asia as well as the virological characteristics of these viruses relative to SARS-CoV-2.
News
Policy & Recommendations
Europe strengthens lab defences against key pathogens
ESWI Chair Colin Russell was featured in a Medscape article on the EU reference laboratories aiming to improve disease surveillance data, including respiratory viruses.
World Immunization Week 2026
Under the theme, “For every generation, vaccines work”, the World Immunization Week will promote how vaccines have safely protected people, families and communities for generations .
News
Policy & Recommendations
The European Commission authorised the first combined COVID-19 and influenza vaccine for people 50 years and older
The EC has recently published on the Union Register of medicinal products the decision granting EU marketing authorisation for mCombriax, an mRNA vaccine to protect people aged 50 years and older against COVID-19 and seasonal influenza.
News
Policy & Recommendations
Council recommendation on the value of immunisation against respiratory infections: a step towards an EU Respiratory Health Plan?
Hosted by Cypriot MEP Michalis Hadjipantela at the European Parliament, the event brought together experts and representatives from various EU institutions.
Respiratory viral infections prime accelerated lung cancer growth
The COVID-19 pandemic has highlighted the long-term consequences of viral pneumonia, yet its impact on cancer development remains unclear.
